Aridis Pharmaceuticals Inc., of San Jose, Calif., set terms for its IPO, disclosing plans to raise $28 million by offering 2.0 million shares priced in a range of $13 to $15. In its filing, the company said insiders expressed interest in purchasing $25 million worth of the shares, or about 89 percent of the deal.